Peninsula Asset Management Inc. increased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 33.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,520 shares of the medical instruments supplier’s stock after acquiring an additional 6,937 shares during the period. Becton Dickinson and comprises 4.4% of Peninsula Asset Management Inc.’s holdings, making the stock its 3rd largest holding. Peninsula Asset Management Inc.’s holdings in Becton Dickinson and were worth $5,891,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Macquarie Group Ltd. boosted its position in Becton Dickinson and by 6.8% in the fourth quarter. Macquarie Group Ltd. now owns 99,767 shares of the medical instruments supplier’s stock valued at $23,141,000 after buying an additional 6,314 shares in the last quarter. Vident Investment Advisory LLC boosted its position in Becton Dickinson and by 36.7% in the fourth quarter. Vident Investment Advisory LLC now owns 4,536 shares of the medical instruments supplier’s stock valued at $971,000 after buying an additional 1,218 shares in the last quarter. Laurel Wealth Advisors Inc. acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $227,000. Hoylecohen LLC acquired a new stake in Becton Dickinson and in the fourth quarter valued at approximately $4,657,000. Finally, Verition Fund Management LLC boosted its position in Becton Dickinson and by 498.4% in the fourth quarter. Verition Fund Management LLC now owns 9,490 shares of the medical instruments supplier’s stock valued at $2,031,000 after buying an additional 7,904 shares in the last quarter. Institutional investors and hedge funds own 83.40% of the company’s stock.
In other Becton Dickinson and news, VP John E. Gallagher sold 5,346 shares of Becton Dickinson and stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $226.08, for a total value of $1,208,623.68. Following the completion of the sale, the vice president now directly owns 9,391 shares of the company’s stock, valued at $2,123,117.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares of the company’s stock, valued at $64,420,918.46. The disclosure for this sale can be found here. Insiders have sold 281,108 shares of company stock valued at $61,321,396 in the last three months. 1.00% of the stock is owned by insiders.
Shares of NYSE BDX opened at $215.50 on Friday. Becton Dickinson and Co has a twelve month low of $175.66 and a twelve month high of $248.39. The firm has a market cap of $58,607.96, a P/E ratio of 22.73, a PEG ratio of 1.60 and a beta of 1.15. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04.
Becton Dickinson and (NYSE:BDX) last announced its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, topping analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the firm earned $2.33 earnings per share. Becton Dickinson and’s quarterly revenue was up 5.4% on a year-over-year basis. research analysts predict that Becton Dickinson and Co will post 10.95 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, March 30th. Investors of record on Friday, March 9th were paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 1.39%. The ex-dividend date of this dividend was Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 31.65%.
BDX has been the subject of several analyst reports. Argus raised their price target on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp initiated coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price target for the company. Bank of America reaffirmed a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research note on Friday, January 19th. Deutsche Bank set a $260.00 price target on shares of Becton Dickinson and and gave the company a “buy” rating in a research note on Friday, December 29th. Finally, Evercore ISI initiated coverage on shares of Becton Dickinson and in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price target for the company. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $240.53.
COPYRIGHT VIOLATION NOTICE: “Becton Dickinson and Co (NYSE:BDX) is Peninsula Asset Management Inc.’s 3rd Largest Position” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/peninsula-asset-management-inc-raises-stake-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.